CORE 017: EARLY PHASE CLINICAL RESEARCH SUPPORT PROJECT SUMMARY/ABSTRACT The overall goal of Early Phase Clinical Research Support (EPCRS) is to catalyze and sustain innovative clinical studies of novel therapies or devices conducted by Vanderbilt-Ingram Cancer Center (VICC) members. VICC investigators have contributed significantly to the understanding of drivers of neoplasia, oncogene addiction, de novo and acquired drug resistance and predictive biomarkers of drug action. EPCRS funds have been essential to the execution of several innovative trials focused on these themes. Twelve investigator- initiated trials (IITs) have been supported by EPCRS during the last funding period. These have generated additional grant support and publications as well as led to larger late phase clinical trials. The Resource Allocation Committee (RAC), created by VICC in 2007, manages the distribution of EPCRS funds from the CCSG and VICC institutional funds to IITs based on scientific merit and priorities of the Center. This is done following review by a committee composed of faculty from multiple cancer disciplines represented in VICC including medical, surgical, radiation and pediatric oncology, cancer genomics, translational research, non-invasive imaging. Criteria used to determine allocation of EPCRS funds mainly include: supportive preclinical data from VICC members, potential to lead to larger multi-institutional pivotal phase II/III trials and extramural funding, feasibility, originality, novel molecular and imaging correlatives, and mentorship for junior investigators. Management of awarded funds is closely monitored by the Medical Director of the Clinical Trials Shared Resource (CTSR), RAC Chairperson, Finance Office, and Human Resources and evaluated on a quarterly basis. Several VICC initiatives and institutional interactions support an excellent environment for the generation of clinical trials potentially eligible for EPCRS support currently and during the next funding period. These include the Center for Targeted Therapies (C2T2), the Innovative Translational Research (ITR) Shared Resource, the Next Generation Sequencing (NGS) Working Group, the Vanderbilt Cancer Imaging Support Laboratory (CISL), the Vanderbilt University Institute of Imaging Sciences (VUIIS) and the Vanderbilt Institute of Chemical Biology (VICB). The C2T2 hosts and coordinates Molecular Tumor Boards, a Visiting Professor (ViP) seminar series, C2T2-Pharma Colloquia, and C2T2 Studios, all representing a source of applications seeking support by EPCRS. These funds also support early phase trials that can lead to larger trials within the National Clinical Trials Network (NCTN), where VICC was awarded a Lead Academic Participating Site (LAPS) grant. During the last funding period, EPCRS has continued to support VICC investigators in the use of their expertise in precision medicine and early drug development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA068485-19
Application #
8934390
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-09-17
Project End
2020-08-31
Budget Start
2015-09-07
Budget End
2016-08-31
Support Year
19
Fiscal Year
2015
Total Cost
$281,051
Indirect Cost
$102,037
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Phelps, Hannah M; Al-Jadiry, Mazin F; Corbitt, Natasha M et al. (2018) Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq. World J Pediatr 14:585-593
Liu, Qi; Herring, Charles A; Sheng, Quanhu et al. (2018) Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biol 16:e2006687
Almodovar, Karinna; Iams, Wade T; Meador, Catherine B et al. (2018) Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol 13:112-123
Greenplate, Allison; Wang, Kai; Tripathi, Rati M et al. (2018) Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies. JCO Precis Oncol 2018:
Mi, Deborah J; Dixit, Shilpy; Warner, Timothy A et al. (2018) Altered glutamate clearance in ascorbate deficient mice increases seizure susceptibility and contributes to cognitive impairment in APP/PSEN1 mice. Neurobiol Aging 71:241-254
Diggins, Kirsten E; Gandelman, Jocelyn S; Roe, Caroline E et al. (2018) Generating Quantitative Cell Identity Labels with Marker Enrichment Modeling (MEM). Curr Protoc Cytom 83:10.21.1-10.21.28
Warner, Jeremy L; Prasad, Ishaan; Bennett, Makiah et al. (2018) SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine. JCO Precis Oncol 2018:
Brown, Judy J; Short, Sarah P; Stencel-Baerenwald, Jennifer et al. (2018) Reovirus-Induced Apoptosis in the Intestine Limits Establishment of Enteric Infection. J Virol 92:
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 2462 publications